On the role of coagulation and fibrinolysis in atherosclerosis

Annals of Epidemiology

Volumn 2, Issue 4, 1992, Pages 427-438

  Juhan Vague, Irène ^a   Collen, Désiré ^b  

^a TIMONE HOSPITAL   (France)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Coagulation; fibrinolysis; lipoprotein (a); plasminogen activator inhibitor 1

Indexed keywords

LIPOPROTEIN A; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD CLOTTING; ENDOTHELIUM INJURY; FIBRIN DEPOSITION; FIBRIN METABOLISM; FIBRINOLYSIS; GENE CONTROL; GENE EXPRESSION REGULATION; HUMAN; INSULIN RESISTANCE; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; PROTEIN SYNTHESIS REGULATION; REVIEW; THROMBOCYTE AGGREGATION; THROMBOGENESIS; VASCULAR ENDOTHELIUM;

ARTERIOSCLEROSIS; BLOOD COAGULATION; FIBRIN; FIBRINOLYSIS; HUMAN; LIPOPROTEIN(A); PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBOSIS;

EID: 0026650470     PISSN: 10472797     EISSN: None     Source Type: Journal    
DOI: 10.1016/1047-2797(92)90092-5     Document Type: Article

References (103)

1. Thrombosis as a factor in the pathogenesis of coronary atherosclerosis
2. Fibrinolysis and atherosclerosis
3. Biological significance of fibrinolysis
4. Metabolism and distribution of fibrinogen. I. Fibrinogen turnover in physiological conditions in humans
5. Repair in arterial tissue. Demonstration of fibrinogen/fibrin in the normal and healing rabbit thoracic aorta by the indirect immunoperoxidase technique
6. Fate of fibrinogen in human arterial intima
7. Plasma levels of fragment d-dimer of crosslinked fibrin during thrombolytic therapy with recombinant tissue-type plasminogen activator (abstract 853)
8. Fibrin degradation products are not specific markers for thrombosis in myocardial infarction
9. Validity of enzymelinked immunosorbent assays of cross-linked fibrin degradation products as a measure of clotlysis
10. Thrombosis and the development of atherosclerosis: Rokitansky revisited
11. Atherosclerosis and the coagulation system
12. Immunochemical characterization of fibrinogen, fibrin I, and fibrin II in human thrombi and atherosclerotic lesions
13. Identification and distribution of fibrinogen, fibrin, and fibrin(ogen) degradation products in atherosclerosis
14. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque
15. Fibrinogen, fibrin and fibrin degradation products in relation to atherosclerosis.
16. Biochemistry of atherosclerosis produced by cholesterol feeding, thrombosis, and injury
17. The release of an immobilized lipoprotein fraction from atherosclerotic lesions by incubation with plasmin
18. Factors influencing the accumulation in fibrous plaque of lipid derived from low density lipoprotein. Part II. Preferential immobilization of lipoprotein(a)
19. Prevalence of Total Coronary Occlusion during the Early Hours of Transmural Myocardial Infarction
20. Fibrinolysis
21. Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-1 gene
22. Plasminogen activator inhibitor: A regulator of ancrod-induced fibrin deposition in rabbits
23. Plasminogen activator inhibitor in the blood of patients with coronary artery disease
24. Plasma tissue plasminogen activator inhibitor levels in coronary artery disease: Correlation with age and serum triglyceride concentrations
25. The extrinsic fibrinolytic system in survivors of myocardial infarction
26. Tissue plasminogen activator activity and inhibition in acute myocardial infarction and angiographically normal coronary arteries
27. Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease
28. Impaired fibrinolytis in coronary artery disease
29. Circadian fluctuations of plasminogen activator inhibitor and tissue plasminogen activator levels in plasma of patients with unstable coronary artery disease and acute myocardial infarction
30. Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease
31. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction
32. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction
33. On the usefulness of fibrinolysis variables in the characterization of a risk group for myocardial reinfarction
34. The fibrinolytic enzyme system and its role in the etiology of thromboembolic disease
35. Circadian variation in the frequency of onset of acute myocardial infarction
36. Plasma plasminogen activator inhibitor-1 in angina pectoris. Influence of plasma insulin and acute-phase response
37. Plasminogen activator and plasminogen activator inhibitor activities in men with coronary artery disease
38. Relationship of insulin response to glucose challenge to severity and rate of progression of coronary atherosclerosis in young survivors of myocardial infarction (abstract)
39. Relationship between blood fibrinolytic activity and body fatness
40. Fibrinolysis in obesity
41. Low vascular fibrinolytic activity in obesity
42. Hyperlipoproteinaemia and reduced fibrinolytic activity in healthy coronary high-risk men
43. Impaired fibrinolytic response to exercise in patients with type-IV hyperlipoproteinaemia
44. Blood fibrinolytic activity in diabetes mellitus and its bearing on ischaemic heart disease and obesity
45. On fibrinolysis in diabetes mellitus
46. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects
47. Relationships between plasma insulin triglyceride, body mass index, and plasminogen activator inhibitor-1
48. Fat distribution and plasminogen activator inhibitor activity in nondiabetic obese women
49. Reduced fibrinolytic response in obese children: Association with high baseline activity of the fast acting plasminogen activator inhibitor (PAI-1)
50. Fibrinolytic variables are related to age, sex, blood pressure, and body build measurements: A cross-sectional study in Norsjö, Sweden
51. Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis.
52. Clinical relevance of high PAI-1 level in patients with idiopathic/recurrent deep venous thrombosis
53. Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients. Relationship with plasma insulin
54. Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus
55. Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease
56. Insulin and atheroma, 20-yr perspective
57. Diabetes, hyperglycaemia, hyperinsulinaemia and atherosclerosis: Epidemiological data
58. Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease. Results from two population studies in Finland
59. Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations
60. Relationship of plasma insulin levels to the incidence of myocardial infarction and coronary heart disease mortality in a middle-aged population
61. Banting Lecture 1988. Role of insulin resistance in human disease
62. The degree of masculine differentiation of obesities. A factor determining predisposition to diabetes, atherosclerosis, gout and uric calculous disease
63. Metformin decreases the high plasminogen activator inhibition capacity, plasma insulin and triglyceride levels in nondiabetic obese subjects
64. Reduction of elevated plasminogen activator inhibitor levels during modest weight loss
65. Impact of physical training on plasminogen activator inhibitor activity in sedentary men
66. Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line Hep G2
67. Plasminogen activator inhibitor 1: Biosynthesis and mRNA levels are increased by insulin in cultured human hepatocytes
68. Reappraisal of the role of insulin in hypertriglyceridemia
69. Secretion of plaminogen activator inhibitor 1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein
70. Effect of low density lipoproteins on secretion of plasminogen activator inhibitor-1 (PAI-1) by human endothelial cells and hepatoma cells
71. 300 Plasminogen activator inhibitor (PA-I) in blood is related to plasma testosterone in men
72. Relationship between smoking and fibrinolytic system with special reference to t-PA and PA inhibitor
73. A new serum type system in man-the Lp system
74. Lp(a): An interloper into the fibrinolytic system?
75. cDNA sequence of human apolipoprotein (a) is homologous to plasminogen
76. The measurement of Lp(a) and its clinical application
77. Lipoprotein Lp(a) and the risk for myocardial infarction
78. Lipoprotein (a) as a strong indicator for cerebrovascular disease
79. Lipoprotein (a) in ischemic cerebrovascular disease: A new approach to the assessment of risk to stroke
80. Lp(a) lipoprotein as a risk factor for myocardial infarction
81. The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. Dependence on serum LDL levels
82. Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography
83. Lipoprotein (a) modulation of endothelial cell surface fibrinolysis and its potential rote in atherosclerosis
84. Binding of Lp(a) to the low density lipoprotein receptor of human fibroblasts
85. Overexpression of human low density lipoprotein receptors leads to accelerated catabolism of Lp(a) lipoprotein in transgenic mice
86. Quantitation and localization of apolipoprotein(a) and B in coronary artery bypass vein grafts resected at re-operation
87. Detection and quantitation of lipoprotein(a) in the arterial wall of 107 coronary bypass patients
88. A potential basis for the thrombotic risks associated with lipoprotein (a)
89. Further characterization of the cellular plasminogen binding site; evidence that plasminogen 2 and lipoprotein(a) compete for the same site
90. Lipoprotein (a), fibrin binding, and plasminogen activation
91. Lipoprotein (a) and plasminogen are immunochemically related
92. Thrombolytic therapy
93. Coronary thrombolysis: Streptokinase or recombinant tissue-type plasminogen activator?
94. Fibrinolytic enhancement by stanazolol: A double blind trial
95. Effect of the sulfonylureas on fibrinolysis
96. Phenformin and ethyloestrenol in recurrent venous thrombosis
97. Synthesis and secretion of plasminogen activators and plasminogen activator inhibitory by endothelial cells
98. Molecular cloning of complementary DNA to mouse tissue plasminogen activator mRNA and its expression during F9 teratocarcinoma cell differentiation
99. Mechanism of induction of tissue-type plasminogen activator mRNA synthesis by retinoic acid in human endothelial cells, (abstract 261)
100. Stimulation of tissue-type plasminogen activator synthesis by retinoids in cultured human endothelial cells and rat tissues in vivo (abstract 321)
101. Analysis of coagulation and fibrinolysis during intravenous infusion of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction
102. Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation